相关实验视频

Updated: Jun 23, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

2024年ASCO生殖尿路癌症研讨会:重点关注细胞癌

Viria Beccia¹, Daniela Arduini¹, Roberto Iacovelli^1,2

¹Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy.

Expert review of anticancer therapy

|June 24, 2024

概括

布罗利祖马布在手术后对高风险细胞癌 (RCC) 患者显示了生存益处. 辅助药尼沃卢马布没有证明有益处,而一线ICI组合在转移性RCC中有效,预后中等/差.

科学领域:

在瘤学瘤学.
生殖尿道癌症生殖尿道癌症
免疫治疗是一种免疫疗法.

背景情况:

随着免疫治疗的进步,细胞癌 (RCC) 的管理正在不断发展.
确定有效的辅助和一线治疗方法对于改善患者的治疗结果至关重要.

研究的目的:

总结2024年美国临床瘤学会 (ASCO) 生殖尿道癌症研讨会关于细胞癌 (RCC) 管理的关键发现.
突出免疫检查点抑制剂 (ICI) 在RCC的辅助和转移环境中的有效性.

主要方法:

在2024年ASCO生殖尿道癌症研讨会上提出的临床试验数据的审查.
分析了Keynote 564,CheckMate 914,CheckMate 9ER和CheckMate 214试验的结果.

主要成果:

在高风险的手术后RCC患者中, pembrolizumab证明了整体生存 (OS) 和无病生存 (DFS) 的优势 (Keynote 564).
辅助剂尼沃卢马布在CheckMate 914试验中没有显示任何益处.
第一线ICI组合证实了转移性RCC患者的生存优势,IMDC预后中等/差 (CheckMate 9ER,CheckMate 214).
对于一线ICI组合,在有利的IMDC风险组患者中没有观察到OS优势.

结论:

布罗利祖马布是迄今为止唯一的ICI,在RCC的辅助环境中证明了生存优势.
基于ICI的组合对于转移性RCC的第一线治疗至关重要,特别是对于中等/低风险组.
这些发现支持对RCC患者进行个性化治疗的持续发展.

关键词:

2024年ASCO生殖尿道癌症研讨会 IMDC 集团是一个IMDC集团.在VEGFR-TKI.生物标志物生物标志物免疫疗法免疫疗法细胞癌瘤是细胞癌.

更多相关视频

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...